{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:55:29Z","timestamp":1791374129847,"version":"4.3.1"},"reference-count":34,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mirt"],"DOI":"10.4274\/mirt.galenos.2026.09471","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:31:24Z","timestamp":1791289884000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of 18F-FDG PET\/CT Radiomics with Tumor Molecular Features in Breast Cancer"],"prefix":"10.4274","author":[{"given":"B\u00fc\u015fra Aydur","family":"P\u00fcren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Usta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz Sami","family":"Saliho\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabiye Uslu","family":"Erdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"ref0","unstructured":"1. World Health Organization. Breast cancer [Internet]. Geneva: World Health Organization. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.32074\/1591-951X-1-20","article-title":"Histological type and typing of breast carcinomas and the WHO classification changes over time","volume":"112","author":"Cserni","year":"2020","unstructured":"2. Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica. 2020;112:25-41.","journal-title":"Pathologica"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implica-tions","volume":"5","author":"Yersal","year":"2014","unstructured":"3. Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implica-tions. World J Clin Oncol. 2014;5:412-424.","journal-title":"World J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010;4:192-208.","DOI":"10.1016\/j.molonc.2010.04.004"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbcan.2009.11.002","article-title":"Tumor heterogeneity: causes and consequences","volume":"1805","author":"Marusyk","year":"2010","unstructured":"5. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805:105-117.","journal-title":"Biochim Biophys Acta"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-784.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. In: Da-tabase of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York: Centre for Reviews and Dissemination; 2011. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK81260\/","DOI":"10.1371\/journal.pone.0021030"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Cardoso","year":"2019","unstructured":"8. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Sen-kus E; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019;30:1194-1220.","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Parlar T. Meme kanseri te\u015fhis ve prognozunda radiomics ile yapay zeka y\u00f6ntemleri kullan\u0131m\u0131 hakk\u0131nda bir inceleme. EJOSAT. 2020;300-306.","DOI":"10.31590\/ejosat.780052"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","unstructured":"10. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R, Boellard R, Dekker A, Aerts HJ. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441-446.","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.breast.2019.10.018","article-title":"Overview of radiomics in breast cancer diagnosis and prognostication","volume":"49","author":"Tagliafico","year":"2020","unstructured":"11. Tagliafico AS, Piana M, Schenone D, Lai R, Massone AM, Houssami N. Overview of radiomics in breast cancer diagnosis and prognostication. Breast. 2020;49:74-80.","journal-title":"Breast"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/cancers13040869","article-title":"Quantitative FDG PET Assessment for oncology therapy","volume":"13","author":"Hirata","year":"2021","unstructured":"12. Hirata K, Tamaki N. Quantitative FDG PET Assessment for oncology therapy. Cancers (Basel). 2021;13:869.","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and proges-terone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update","volume":"144","author":"Allison","year":"2020","unstructured":"13. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and proges-terone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144:545-563.","journal-title":"Arch Pathol Lab Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American So-ciety of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Fo-cused Update","volume":"142","author":"Wolff","year":"2018","unstructured":"14. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human epidermal growth factor receptor 2 testing in breast cancer: American So-ciety of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Fo-cused Update. Arch Pathol Lab Med. 2018;142:1364-1382.","journal-title":"Arch Pathol Lab Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","unstructured":"15. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ; Pan-el members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206-2223.","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","unstructured":"16. Nioche C, Orlhac F, Boughdad S, Reuz\u00e9 S, Goya-Outi J, Robert C, Pellot-Barakat C, Soussan M, Frouin F, Buvat I. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786-4789.","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"the image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","unstructured":"17. Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Ba-kas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, De-peursinge A, Desseroit MC, Dinapoli N, Dinh CV, Echegaray S, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, G\u00f6tz M, Guckenberger M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leije-naar RTH, Lenkowicz J, Lippert F, Losneg\u00e5rd A, Maier-Hein KH, Morin O, M\u00fcller H, Napel S, Ni-oche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Socarras Fernandez J, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, L\u00f6ck S. the image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328-338.","journal-title":"Radiology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.3390\/app15126453","article-title":"PET radi-omics signatures and artificial intelligence for decoding immunotherapy response in advanced cutaneous squamous cell carcinoma: a retrospective single-center study","volume":"15","author":"Manco","year":"2025","unstructured":"18. Manco L, Proietti I, Scribano G, Pirisino R, Bagni O, Potenza C, Pellacani G, Filippi L. PET radi-omics signatures and artificial intelligence for decoding immunotherapy response in advanced cutaneous squamous cell carcinoma: a retrospective single-center study. Applied Sciences. 2025;15:6453.","journal-title":"Applied Sciences"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00259-022-06001-6","article-title":"Joint EANM\/SNMMI guideline on radiomics in nuclear medicine : Jointly supported by the EANM Physics Committee and the SNMMI Physics, Instrumentation and Data Sciences Council","volume":"50","author":"Hatt","year":"2023","unstructured":"19. Hatt M, Krizsan AK, Rahmim A, Bradshaw TJ, Costa PF, Forgacs A, Seifert R, Zwanenburg A, El Naqa I, Kinahan PE, Tixier F, Jha AK, Visvikis D. Joint EANM\/SNMMI guideline on radiomics in nuclear medicine : Jointly supported by the EANM Physics Committee and the SNMMI Physics, Instrumentation and Data Sciences Council. Eur J Nucl Med Mol Imaging. 2023;50:352-375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Orlhac F, Soussan M, Chouahnia K, Martinod E, Buvat I. 18F-FDG PET-derived textural indices reflect tissue-specific uptake pattern in non-small cell lung cancer. PLoS One. 2015;10:e0145063.","DOI":"10.1371\/journal.pone.0145063"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.semcancer.2020.04.002","article-title":"Radiomics in breast cancer classification and prediction","volume":"72","author":"Conti","year":"2021","unstructured":"21. Conti A, Duggento A, Indovina I, Guerrisi M, Toschi N. Radiomics in breast cancer classification and prediction. Semin Cancer Biol. 2021;72:238-250.","journal-title":"Semin Cancer Biol"},{"key":"ref21","unstructured":"22. Nioche C, Orlhac F, Buvat I. LIFEx texture user guide [Internet]. Available from: https:\/\/www.lifexsoft.org\/index.php\/resources\/documentation"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/s41598-017-01524-7","article-title":"Metabolic radiomics for pretreatment 18F-FDG PET\/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neo-adjuvant chemotherapy, and prognosis","volume":"7","author":"Ha","year":"2017","unstructured":"23. Ha S, Park S, Bang JI, Kim EK, Lee HY. Metabolic radiomics for pretreatment 18F-FDG PET\/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neo-adjuvant chemotherapy, and prognosis. Sci Rep. 2017;7:1556.","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00259-017-3770-9","article-title":"[18F]FDG PET\/CT features for the molecular characterization of primary breast tumors","volume":"44","author":"Antunovic","year":"2017","unstructured":"24. Antunovic L, Gallivanone F, Sollini M, Sagona A, Invento A, Manfrinato G, Kirienko M, Tinterri C, Chiti A, Castiglioni I. [18F]FDG PET\/CT features for the molecular characterization of primary breast tumors. Eur J Nucl Med Mol Imaging. 2017;44:1945-1954.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00259-017-3830-1","article-title":"Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer","volume":"45","author":"Moscoso","year":"2018","unstructured":"25. Moscoso A, Ruibal \u00c1, Dom\u00ednguez-Prado I, Fern\u00e1ndez-Ferreiro A, Herranz M, Albaina L, Argibay S, Silva-Rodr\u00edguez J, Pardo-Montero J, Aguiar P. Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer. Eur J Nucl Med Mol Imaging. 2018;45:196-206.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Araz M, Soydal \u00c7, G\u00fcnd\u00fcz P, K\u0131rm\u0131z\u0131 A, Bak\u0131rarar B, Dizbay Sak S, \u00d6zkan E. Can radiomics analyses in 18F-FDG PET\/CT images of primary breast carcinoma predict hormone receptor sta-tus? Mol Imaging Radionucl Ther. 2022;31:49-56.","DOI":"10.4274\/mirt.galenos.2022.59140"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/MNM.0000000000001019","article-title":"Comparison of the volumetric and radiomics findings of 18F-FDG PET\/CT images with immunohistochemical prognostic factors in local\/locally advanced breast cancer","volume":"40","author":"Acar","year":"2019","unstructured":"27. Acar E, Turgut B, Yi\u011fit S, Kaya G. Comparison of the volumetric and radiomics findings of 18F-FDG PET\/CT images with immunohistochemical prognostic factors in local\/locally advanced breast cancer. Nucl Med Commun. 2019;40:764-772.","journal-title":"Nucl Med Commun"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Soussan M, Orlhac F, Boubaya M, Zelek L, Ziol M, Eder V, Buvat I. Relationship between tumor heterogeneity measured on FDG-PET\/CT and pathological prognostic factors in invasive breast cancer. PLoS One. 2014;9:e94017.","DOI":"10.1371\/journal.pone.0094017"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00259-017-3641-4","article-title":"Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and tex-tural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients","volume":"44","author":"Lemarignier","year":"2017","unstructured":"29. Lemarignier C, Martineau A, Teixeira L, Vercellino L, Espi\u00e9 M, Merlet P, Groheux D. Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and tex-tural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:1145-1154.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12149-021-01688-3","article-title":"Prediction of HER2 expression in breast can-cer by combining PET\/CT radiomic analysis and machine learning","volume":"36","author":"Chen","year":"2022","unstructured":"30. Chen Y, Wang Z, Yin G, Sui C, Liu Z, Li X, Chen W. Prediction of HER2 expression in breast can-cer by combining PET\/CT radiomic analysis and machine learning. Ann Nucl Med. 2022;36:172-182.","journal-title":"Ann Nucl Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-030-65768-0_1","article-title":"Glucose metabolism in cancer: the warburg effect and beyond","volume":"1311","author":"Bose","year":"2021","unstructured":"31. Bose S, Zhang C, Le A. Glucose metabolism in cancer: the warburg effect and beyond. Adv Exp Med Biol. 2021;1311:3-15.","journal-title":"Adv Exp Med Biol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"13376","DOI":"10.3390\/ijms252413376","article-title":"The biological roles and clinical applications of the PI3K\/AKT pathway in targeted therapy resistance in HER2-Positive breast cancer: a comprehensive review","volume":"25","author":"Zhong","year":"2024","unstructured":"32. Zhong H, Zhou Z, Wang H, Wang R, Shen K, Huang R, Wang Z. The biological roles and clinical applications of the PI3K\/AKT pathway in targeted therapy resistance in HER2-Positive breast cancer: a comprehensive review. Int J Mol Sci. 2024;25:13376.","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.3390\/cancers13122922","article-title":"Targeting mTOR and glycolysis in HER2-positive breast cancer","volume":"13","author":"RW","year":"2021","unstructured":"33. Holloway RW, Marignani PA. Targeting mTOR and glycolysis in HER2-positive breast cancer. Cancers (Basel). 2021;13:2922.","journal-title":"Cancers (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-015-3070-1","article-title":"Association between 18F-FDG uptake and molecular subtype of breast cancer","volume":"42","author":"Kitajima","year":"2015","unstructured":"34. Kitajima K, Fukushima K, Miyoshi Y, Nishimukai A, Hirota S, Igarashi Y, Katsuura T, Maruyama K, Hirota S. Association between 18F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:1371-1377.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Molecular Imaging and Radionuclide Therapy"],"original-title":[],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:29:32Z","timestamp":1791372572000},"score":1,"resource":{"primary":{"URL":"https:\/\/mirt.tsnmjournals.org\/articles\/association-of-lesssupgreater18lesssupgreaterf-fdg-petct-radiomics-with-tumor-molecular-features-in-breast-cancer\/doi\/mirt.galenos.2026.09471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":34,"URL":"https:\/\/doi.org\/10.4274\/mirt.galenos.2026.09471","relation":{},"ISSN":["2146-1414","2147-1959"],"issn-type":[{"value":"2146-1414","type":"print"},{"value":"2147-1959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]}}}